The short version of peptide research fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-25. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
One of the key classifications is between traditional small molecule drugs; usually derived from chemical synthesis and biological medical products; which include recombinant proteins, vaccines, blood products used therapeutically (such as IVIG), gene therapy, and cell therapy (for instance, stem cell therapies). Pharmaceuticals or drugs or medicines are classified into various other groups besides their origin on the basis of pharmacological properties like mode of action and their pharmacological action or activity, such as by chemical properties, mode or route of administration, biological system affected, or therapeutic effects. An elaborate and widely used classification system is the Anatomical Therapeutic Chemical Classification System (ATC system). The World Health Organization keeps a list of essential medicines. Pharmaceuticals may also be described as "specialty", independent of other classifications, which is an ill-defined class of drugs that might be difficult to administer, require special handling during administration, require patient monitoring during and immediately after administration, have particular regulatory requirements restricting their use, and are generally expensive relative to other drugs.
== Calculations using calibration curve == Many analysts do not employ analytical equations for isotope dilution analysis. Instead, they rely on building a calibration curve from mixtures of the natural primary standard (A*) and the isotopically enriched standard (the spike, B). Calibration curves are obtained by plotting measured isotope ratios in the prepared blends against the known ratio of the sample mass to the mass of the spike solution in each blend. Isotope dilution calibration plots sometimes show nonlinear relationships and in practice polynomial fitting is often performed to empirically describe such curves. When calibration plots are markedly nonlinear, one can bypass the empirical polynomial fitting and employ the ratio of two linear functions (known as Padé approximant) which is shown to describe the curvature of isotope dilution curves exactly.
In the late-1970s, Ruben Rausing worked on Operation Flood, a joint venture between the World Food Programme, the World Bank, and Tetra Pak to supply Western milk surplus to Indian households. The company established its Food for Development office in 2000, through which it works with local governments, NGOs and farmers to develop school milk programmes, a cause it has supported since 1962, when the first school milk programme supported by Tetra Pak launched in Mexico. After the 2008 Chinese melamine scandal, the Chinese government tightened regulations on safety and environmental standards, damaging the country's market for packaged milk and infant formula. Tetra Pak had nothing to do with the scandal; however, Tetra Pak China established a training program that was delivered by a food safety school, DVDs, and books, resulting in over 30 farms meeting EU quality standards, according to Tetra Pak China. The effort also included a push to reduce waste by advising customers on recycling and working alongside the World Wildlife Fund to reduce carbon dioxide emissions. The Financial Times indicated this was not a philanthropic act, but a way to establish a future for the company by ensuring there was always a market for their products. In 2015, Tetra Pak in collaboration with DeLavel, signed a five-year agreement with the Dairy Association of China to provide training to 150 Chinese dairy farm managers, providing them with the skills required to run larger-scale dairy farms. It is unclear if this initiative was voluntary or paid for.
Chenpi – is sun-dried tangerine (mandarin) peel used as a traditional seasoning in Chinese cooking and traditional medicine. Dried cherries Chipotle – a smoked, dried jalapeño pepper. Coconut – can be dried whole or halved. A common product is coconut that has been dried and shredded. Dried cranberry – is made by partially dehydrating fresh cranberries, a process similar to making grapes into raisins.
Sources: en.wikipedia.org
The modern method of embalming involves the injection of various chemical solutions into the arterial network of the body to primarily disinfect and slow the decomposition process. William Harvey, the 17th century English physician who was the first to detail the system of blood circulation, made his discoveries by injecting colored solutions into corpses. The Scottish surgeon William Hunter was the first to apply these methods to the art of embalming as part of mortuary practice. He wrote a widely read report on the appropriate methods for arterial and cavity embalming in order to preserve bodies for burial. His brother, John Hunter, applied these methods and advertised his embalming services to the general public from the mid-18th century. One of his more notorious clients was dentist Martin Van Butchell. When his wife Mary died on 14 January 1775, he had her embalmed as an attraction to draw more customers. Hunter injected the body with preservatives and color additives that gave a glow to the corpse's cheeks, replaced her eyes with glass eyes, and dressed her in a fine lace dress. The body was embedded in a layer of plaster of Paris in a glass-topped coffin. Butchell exhibited the body in the window of his home and many Londoners came to see it; however, Butchell drew criticism for the display. A rumor, possibly started by Butchell himself, claimed that his wife's marriage certificate had specified that her husband would only have control over her estate after her death for as long as her body was kept unburied.
Cooper Green Mercy Health Services is owned by Jefferson County, Alabama. It first opened as Mercy Hospital in 1972 as a 319-bed acute care facility and was renamed for former Birmingham mayor Cooper Green three years later. It is located at 1515 6th Avenue South, adjacent to UAB Hospital on Birmingham's Southside. After four decades, the hospital closed its inpatient beds on December 31, 2012, and transitioned to a multi-specialty outpatient health service organization. The health service organization offers both primary and specialty care, behavioral health, and urgent care. In addition, it offers an onsite pharmacy, radiology, and clinical laboratory, as well as OT, PT, Speech and Respiratory Therapy. The health service organization continues to offer healthcare to the citizens of Jefferson County regardless of their ability to pay. Funding for indigent care was established by the Alabama Legislature in 1965, using revenues collected from county sales and liquor taxes. As a county-owned health service organization, Cooper Green Mercy provides healthcare services to all Jefferson County residents with fees based on family size and income. The health service organization coordinates with the University of Alabama at Birmingham (UAB) Health System as a training site for medical residents and to provide patients with diagnostic tests and procedures not provided onsite. In addition, many of the specialty clinics are staffed by UAB faculty who practice part-time at the facility.
==== Gastrointestinal and colorectal cancer ==== Reviews of preliminary clinical trials on people with colorectal or gastrointestinal cancer suggest that soy isoflavones may have a slight protective effect against such cancers.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.